Q1 2018 13F Holders as of 3/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
19.3M
-
Number of holders
-
317
-
Total 13F shares, excl. options
-
24.3M
-
Shares change
-
+384K
-
Total reported value, excl. options
-
$4B
-
Value change
-
+$70.5M
-
Put/Call ratio
-
1.44
-
Number of buys
-
146
-
Number of sells
-
-150
-
Price
-
$165.16
Significant Holders of LIGAND PHARMACEUTICALS INC - Common Stock (LGND) as of Q1 2018
356 filings reported holding LGND - LIGAND PHARMACEUTICALS INC - Common Stock as of Q1 2018.
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) has 317 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.3M shares
.
Largest 10 shareholders include BlackRock Inc. (3.01M shares), VANGUARD GROUP INC (1.94M shares), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (1.03M shares), STATE STREET CORP (950K shares), JANUS HENDERSON GROUP PLC (872K shares), AMERIPRISE FINANCIAL INC (772K shares), Knott David M (553K shares), Bank of New York Mellon Corp (519K shares), VICTORY CAPITAL MANAGEMENT INC (510K shares), and Conestoga Capital Advisors, LLC (471K shares).
This table shows the top 317 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.